Effect of clopidogrel added to aspirin in patients with atrial fibrillation

Cited by (1,000)

Items 101–200 of 1,000

1. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018
   David B. Brieger, John V. Amerena, John Attia, Beata V. Bajorek, Kim Hoe Chan, Cia Connell, Ben Freedman, Caleb Ferguson, Tanya L Hall, Haris M. Haqqani et al. · 2018 · Heart Lung and Circulation
2. Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice: Insight From the Real-Life Global Survey Evaluating Patients With Atrial Fibrillation International Registry
   Chiang, Chern-En, Naditch-Brûlé, Lisa, Murin, Jan, Goethals, Marnix, Inoue, Hiroshi, O’Neill, James, Silva-Cardoso, Jose, Zharinov, Oleg, Gamra, Habib, Alam, Samir et al. · 2012 · Circulation: Arrhythmia and Electrophysiology
3. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis
   Chatree Chai‐Adisaksopha, Mark Andrew Crowther, Tetsuya Isayama, Wendy Lim · 2014 · Blood
4. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion
   Bernhard Meier, Yuri Blaauw, Ahmed Aziz Khattab, Torsten Lewalter, Horst Sievert, Claudio Tondo, Michael Glikson, ESC Scientific Document Group, Gregory Y.H. Lip, José Ramón López-Mínguez et al. · 2014 · EP Europace
5. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients
   Gregory Y.H. Lip, Allison V. Keshishian, Xiaoyan Li, Melissa Hamilton, Cristina Masseria, Kiran B. Gupta, Xuemei Luo, Jack Mardekian, Keith E. Friend, Anagha Nadkarni et al. · 2018 · Stroke
6. Atrial fibrillation: the current epidemic.
   Carlos Arturo Morillo, Amitava Banerjee, Pablo Perel, David Alexander Wood, Xavier Jouven · 2017 · Europe PMC (PubMed Central)
7. Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study
   Marijon, Eloi, Le Heuzey, Jean-Yves, Connolly, Stuart, Yang, Sean, Pogue, Janice, Brueckmann, Martina, Eikelboom, John, Themeles, Ellison, Ezekowitz, Michael, Wallentin, Lars et al. · 2013 · Circulation
8. National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011
   Kate Kirley, Dima Mazen Qato, Rachel Kornfield, Randall Scott Stafford, G. Caleb Alexander · 2012 · Circulation Cardiovascular Quality and Outcomes
9. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting
   Kurt Huber, Felicita Andreotti, Harald Arnesen, Juhani K.E. Airaksinen, Thomas Cuisset, Paulus F. Kirchhof, Francisco R. Marín, Gregory Y.H. Lip · 2009 · Thrombosis and Haemostasis
10. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study
    Amitava Banerjee, Deirdre A. Lane, Christian Tobias Torp-Pedersen, Gregory Y.H. Lip · 2011 · Thrombosis and Haemostasis
11. Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk
    Jonathan Chong Hsu, Thomas M. Maddox, Kevin F. Kennedy, David F. Katz, Lucas Marzec, Steven A. Lubitz, Anil K. Gehi, Mintu P. Turakhia, Gregory M. Marcus · 2016 · JAMA Cardiology
12. Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter
    John A. Cairns, Stuart J. Connolly, Sean McMurtry, Michael Stephenson, Mario R. Talajic · 2011 · Canadian Journal of Cardiology
13. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    Gordon Henry Guyatt, Elie A. Akl, Mark Andrew Crowther, David D. Gutterman, Holger J. Schü nemann · 2013
14. Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation
    Gregory Y.H. Lip, Torben Bjerregaard Larsen, Flemming Skjøth, Lars Hvilsted Rasmussen · 2012 · Journal of the American College of Cardiology
15. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments
    Jessica L. Mega, Tabassome Simon · 2015 · The Lancet
16. Bleeding risk assessment and management in atrial fibrillation patients
    Laurent Fauchier, Elaine M. Hylek, Eve Knight, Deirdre A. Lane, Marcel M Levi, Francisco R. Marín, Gualtiero Palareti, Collet Jp, Andrea Rubboli, Daniela Poli et al. · 2011 · Thrombosis and Haemostasis
17. Ibrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies
    Joseph James Shatzel, Samuel R. Olson, D.L. Tao, Owen J. T. McCarty, Alexey Valeryevich Danilov, Thomas G. DeLoughery · 2017 · Journal of Thrombosis and Haemostasis
18. Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin
    Ammar Majeed, Hun-Gyu Hwang, Stuart J. Connolly, John W. Eikelboom, Michael D. Ezekowitz, Lars C. Wallentin, Martina Brueckmann, Mandy Fraessdorf, Salim Yusuf, Sam Schulman · 2013 · Circulation
19. Moving the Tipping Point
    Mark H. Eckman, Daniel E. Singer, Jonathan M. Rosand, Steven Mark Greenberg · 2010 · Circulation Cardiovascular Quality and Outcomes
20. 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
    Jeffrey L. Anderson, Cynthia D. Adams, Elliott Marshall Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin et al. · 2013 · Circulation
21. 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation
    Laurent Macle, John A. Cairns, Kori Leblanc, Teresa S.M. Tsang, Allan Cameron Skanes, Jafna L. Cox, Jeff S. Healey, Alan Bell, Louise Pilote, Jason G. Andrade et al. · 2016 · Canadian Journal of Cardiology
22. Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
    Karen L. Furie, Larry B. Goldstein, Gregory W. Albers, Pooja Khatri, Ron R. Neyens, Mintu P. Turakhia, Tanya N. Turan, Kathryn Wood · 2012 · Stroke
23. Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation
    Matthew William Sherwood, James Demetrios Douketis, Manesh R. Patel, Jonathan Paul Piccini, Anne S. Hellkamp, Yuliya V. Lokhnygina, Alex C. Spyropoulos, Graeme J. Hankey, Daniel E. Singer, Christopher C. Nessel et al. · 2014 · Circulation
24. New Oral Anticoagulants in Elderly Adults: Evidence from a Meta‐Analysis of Randomized Trials
    Partha Sardar, Saurav Chatterjee, Shobhana Chaudhari, Gregory Y.H. Lip · 2014 · Journal of the American Geriatrics Society
25. Risk of Bleeding With Dabigatran in Atrial Fibrillation
    Inmaculada Hernandez, Seo Hyon Baik, Antonio Piñera, Yuting Zhang · 2014 · JAMA Internal Medicine
26. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA
    Mattias Wieloch, Anders Själander, Viveka Frykman, Mårten Rosenqvist, Niclas Eriksson, Peter J. Svensson · 2011 · European Heart Journal
27. Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
    Amanda R. Harrington, Edward P. Armstrong, Paul E. Nolan, Daniel C. Malone · 2013 · Stroke
28. Atrial Fibrillation
    Mina K. Chung, Marwan M. Refaat, Win-Kuang Shen, Valentina Kutyifa, Yong‐Mei Cha, Luigi Di Biase, Adrian M Baranchuk, Rachel Lampert, Andrea Natale, John D. Fisher et al. · 2020 · Journal of the American College of Cardiology
29. Hypertension and Atrial Fibrillation
    Paolo Verdecchia, Fabio Angeli, Gianpaolo Reboldi · 2018 · Circulation Research
30. Irbesartan in Patients with Atrial Fibrillation
    The ACTIVE I Investigators · 2011 · New England Journal of Medicine
31. Atrial Fibrillation
    PETER J. ZIMETBAUM · 2017 · Annals of Internal Medicine
32. Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism
    Manuj Sharma, Victoria R. Cornelius, Jignesh Prakash Patel, Graham Davies, Mariam Molokhia · 2015 · Circulation
33. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options—a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference
    Paulus F. Kirchhof, Gregory Y.H. Lip, Isabelle C. Van Gelder, Jeroen Joost Bax, Elaine M. Hylek, Stefan Kääb, Ulrich Schotten, Karl Wegscheider, Giuseppe Boriani, Axel Brandes et al. · 2011 · EP Europace
34. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease
    Álvaro Avezum, Renato D. Lópes, Phillip J. Schulte, Fernando Tomas Lanas, Bernard John Gersh, Michael Hanna, Prem Pais, Çetin Erol, Rafael Díaz, Maria Cecilia Bahit et al. · 2015 · Circulation
35. Sex Differences in Stroke Risk Among Older Patients With Recently Diagnosed Atrial Fibrillation
    Cynthia A. Jackevicius · 2012 · JAMA
36. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
    Neena S. Abraham, Mark Andrew Hlatky, Elliott Marshall Antman, Deepak L. Bhatt, David J. Bjorkman, Craig B. Clark, Curt Daniel Furberg, David A. Johnson, Charles J. Kahi, Loren Laine et al. · 2010 · Journal of the American College of Cardiology
37. Antiplatelet agents for the treatment and prevention of atherothrombosis
    Carlo Patrono, Felicita Andreotti, Harald Arnesen, Lina Badimón, Colin Baigent, Jean‐Philippe Collet, Raffaele De Caterina, Dietrich C. Gulba, Kurt Huber, Steen Husted et al. · 2011 · European Heart Journal
38. Atrial fibrillation
    Gregory Y.H. Lip, Laurent Fauchier, Saul B. Freedman, Isabelle C. Van Gelder, Andrea Natale, Carola Gianni, Stanley Nattel, Tatjana Potpara, Michiel Rienstra, Hung‐Fat Tse et al. · 2016 · Nature Reviews Disease Primers
39. Patients with atrial fibrillation and coronary artery disease – Double trouble
    Ewelina Michniewicz, Elżbieta Młodawska, Paulina Łopatowska, Anna Tomaszuk−Kazberuk, Jolanta Małyszko · 2017 · Advances in Medical Sciences
40. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary
    pre-diabetes Task Force on diabetes · 2014 · Diabetes and Vascular Disease Research
41. An Expert Consensus Document on the Management of Cardiovascular Manifestations of Fabry Disease
    Aleš Linhart, Dominique Paul Germain, Iacopo Olivotto, Mohammed Majid Akhtar, Aris Anastasakis, Derralynn A. Hughes, Mehdi Namdar, Maurizio Pieroni, Albert Alain Hagège, Franco Cecchi et al. · 2020 · European Journal of Heart Failure
42. Age as a Risk Factor for Stroke in Atrial Fibrillation Patients
    Marinigh, Ricarda, Lip, Gregory Y.H., Fiotti, Nicola, Giansante, Carlo, Lane, Deirdre A. · 2010 · Journal of the American College of Cardiology
43. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary—a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
    Gregory Y.H. Lip, Kurt Huber, Felicita Andreotti, Harald Arnesen, Juhani K.E. Airaksinen, Thomas Cuisset, Paulus F. Kirchhof, Francisco R. Marín · 2010 · European Heart Journal
44. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline)
    L. Samüel Wann, Anne B. Curtis, Craig T. January, Kenneth A. Ellenbogen, James E. Lowe, N.A. Mark Estes, Richard L. Page, Michael D. Ezekowitz, David J. Slotwiner, Warren M. Jackman et al. · 2010 · Journal of the American College of Cardiology
45. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter
    M. S. Arakelyan, Leo A. Bockeria, Elena Vasilieva, Golitsyn Sp, Elena Zelikovna Golukhova, M. V. Gorev, Karapet V. Davtyan, Oksana M. Drapkina, Кропачева Екатерина Станиславовна, Е. А. Kuchinskaya et al. · 2021 · Russian Journal of Cardiology
46. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis
    Gregory Y.H. Lip, Felicita Andreotti, Laurent Fauchier, Kurt Huber, Elaine M. Hylek, Eve Knight, Deirdre A. Lane, Marcel M Levi, Francisco R. Marín, Gualtiero Palareti et al. · 2011 · EP Europace
47. Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation
    Tze‐Fan Chao, Chia‐Jen Liu, Yenn‐Jiang Lin, Shih‐Lin Chang, Li‐Wei Lo, Yu‐Feng Hu, Ta‐Chuan Tuan, Jo‐Nan Liao, Fa‐Po Chung, Tzeng‐Ji Chen et al. · 2018 · Circulation
48. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study
    Stuart J. Connolly, Lars C. Wallentin, Michael D. Ezekowitz, John W. Eikelboom, Jonas Oldgren, Paul A. Reilly, Martina Brueckmann, Janice M. Pogue, Marco Alings, John V. Amerena et al. · 2013 · Circulation
49. The frailty index in Europeans: association with age and mortality
    Román Romero‐Ortuño, Rose Anne Kenny · 2012 · Age and Ageing
50. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention
    Davide Capodanno, Roxana Mehran, Marco Valgimigli, Usman Baber, Stephan Windecker, Pascal Vranckx, George Dangas, Fabiana Rollini, Takeshi Kimura, Jean‐Philippe Collet et al. · 2018 · Nature Reviews Cardiology
51. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation
    George Ntaios, Vasileios Papavasileiou, Konstantinos P. Makaritsis, Konstantinos N. Vemmos, Patrik Michel, Gregory Y.H. Lip · 2017 · Stroke
52. Fibrotic Atrial Cardiomyopathy, Atrial Fibrillation, and Thromboembolism
    Benjamin J. Hirsh, Robert S. Copeland-Halperin, Jonathan L. Halperin · 2015 · Journal of the American College of Cardiology
53. Early Safety and Efficacy of Percutaneous Left Atrial Appendage Suture Ligation
    Matthew J. Price, Douglas N Gibson, Steven Joseph Yakubov, Jason C. Schultz, Luigi Di Biase, Andrea Natale, J. David Burkhardt, Ashish Pershad, Timothy Byrne, Brett Gidney et al. · 2014 · Journal of the American College of Cardiology
54. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline
    Catharina J.M. Klijn, Maurizio Paciaroni, Eivind Berge, Eleni Korompoki, Janika Kõrv, Avtar Lal, Jukka Putaala A, David John Werring · 2019 · European Stroke Journal
55. Drug attrition during pre-clinical and clinical development: Understanding and managing drug-induced cardiotoxicity
    Nicola Ferri, Peter K. S. Siegl, Alberto Corsini, Joerg Herrmann, Amir Lerman, Renée Benghozi · 2013 · Pharmacology & Therapeutics
56. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding
    Theodore Earl Warkentin, Peter J. Margetts, Stuart J. Connolly, Andre L. Lamy, Chris Ricci, John W. Eikelboom · 2012 · Blood
57. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants
    Pancholy, Samir B., Sharma, Parikshit S., Pancholy, Dipti S., Patel, Tejas M., Callans, David J., Marchlinski, Francis E. · 2014 · The American Journal of Cardiology
58. Warfarin in atrial fibrillation patients with moderate chronic kidney disease
    Hart, Robert G., Pearce, Lesly A., Asinger, Richard W., Herzog, Charles A. · 2011 · Clinical Journal of the American Society of Nephrology
59. The Use of Dabigatran in Elderly Patients
    Matthieu M. Legrand · 2011 · Archives of Internal Medicine
60. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy
    Stefan Agewall, Marco Cattaneo, J.‐P. Collet, Felicita Andreotti, Gregory Y.H. Lip, Freek W.A. Verheugt, Kurt Huber, Erik Lerkevang Grove, João Morais, Steen Husted et al. · 2013 · European Heart Journal
61. Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF
    Sean D. Pokorney, Jonathan Paul Piccini, Susanna R. Stevens, Manesh R. Patel, Karen S. Pieper, Jonathan L. Halperin, GÜNTER E. BREITHARDT, Daniel E. Singer, Graeme J. Hankey, Werner Hacke et al. · 2016 · Journal of the American Heart Association
62. Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms
    Francesco Violi, Elsayed Z. Soliman, Pasquale Pignatelli, Daniele Pastori · 2016 · Journal of the American Heart Association
63. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension
    Manolis, Athanasios J., Rosei, Enrico Agabiti, Coca, Antonio, Cifkova, Renata, Erdine, Serap E., Kjeldsen, Sverre, Lip, Gregory Y.H., Narkiewicz, Krzysztof, Parati, Gianfranco, Redon, Josep et al. · 2012 · Journal of Hypertension
64. Severe Renal Impairment and Stroke Prevention in Atrial Fibrillation
    Marinigh, Ricarda, Lane, Deirdre A., Lip, Gregory Y.H. · 2011 · Journal of the American College of Cardiology
65. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial
    Breithardt, Günter, Baumgartner, Helmut, Berkowitz, Scott D., Hellkamp, Anne S., Piccini, Jonathan P., Stevens, Susanna R., Lokhnygina, Yuliya, Patel, Manesh R., Halperin, Jonathan L., Singer, Daniel E. et al. · 2014 · European Heart Journal
66. Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial
    Jonas Oldgren, Marco Alings, Harald Darius, Hans-Christoph Diener, John Eikelboom, Michael D. Ezekowitz, Gabriel Kamensky, Paul A. Reilly, Sean Yang, Salim Yusuf et al. · 2011 · Annals of Internal Medicine
67. The State of the Art
    Daniel P. Morin, Michael L. Bernard, Christopher A. Madias, Paul A. Rogers, Sudarone Thihalolipavan, N.A. Mark Estes · 2016 · Mayo Clinic Proceedings
68. Meta-analysis: Effect of Patient Self-testing and Self-management of Long-Term Anticoagulation on Major Clinical Outcomes
    Hanna E. Bloomfield, Ange Krause, Nancy L. Greer, Brent C Taylor, Roderick H. MacDonald, Indulis R. Rutks, Preetham Reddy, Timothy J Wilt · 2011 · Annals of Internal Medicine
69. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta‐analysis of randomized controlled trials
    Chatree Chai‐Adisaksopha, Christopher Hillis, Tetsuya Isayama, Wendy Lim, Alfonso Iorio, Mark Andrew Crowther · 2015 · Journal of Thrombosis and Haemostasis
70. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics
    Sophie Testa, Armando Tripodi, Cristina Legnani, Vittorio Pengo, Rosanna Abbate, Claudia Dellanoce, Paolo Carraro, Luisa Salomone, Rita Paniccia, Oriana Paoletti et al. · 2015 · Thrombosis Research
71. Cardiovascular drug therapy in the elderly: benefits and challenges
    Fleg, Jerome L., Aronow, Wilbert S., Frishman, William H. · 2011 · Nature Reviews Cardiology
72. Improving Stroke Risk Stratification in Atrial Fibrillation
    Gregory Y.H. Lip, Jonathan L. Halperin · 2010 · The American Journal of Medicine
73. Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke
    Peter Malcolm Rothwell, Ale Algra, Pierre Amarenco · 2011 · The Lancet
74. New Oral Anticoagulants and the Risk of Intracranial Hemorrhage
    Saurav Chatterjee, Partha Sardar, Giuseppe Biondi‐Zoccai, Dharam J. Kumbhani · 2013 · JAMA Neurology
75. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy
    Michiel Coppens, John W. Eikelboom, Robert G. Hart, Salim Yusuf, Gregory Y.H. Lip, Paul Dorian, Olga Shestakovska, Stuart J. Connolly · 2012 · European Heart Journal
76. Secondary stroke prevention: challenges and solutions
    José Gutierrez, Charles C. Esenwa · 2015 · Vascular Health and Risk Management
77. Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: An analysis from ASSERT
    Elizabeth S. Kaufman, Carsten Walter Israel, Girish M. Nair, Luciana Armaganijan, Syamkumar Divakaramenon, Georges H. Mairesse, Axel Brandes, Eugene Crystal, Otto Costantini, Roopinder Kaur Sandhu et al. · 2012 · Heart Rhythm
78. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
    Neena S. Abraham, Mark Andrew Hlatky, Elliott Marshall Antman, Deepak L. Bhatt, David J. Bjorkman, Craig B. Clark, Curt Daniel Furberg, David A. Johnson, Charles J. Kahi, Loren Laine et al. · 2010 · The American Journal of Gastroenterology
79. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial
    Diener, Hans-Christoph, Eikelboom, John, Connolly, Stuart J, Joyner, Campbell D, Hart, Robert G, Lip, Gregory YH, O'Donnell, Martin, Hohnloser, Stefan H, Hankey, Graeme J, Shestakovska, Olga et al. · 2012 · The Lancet Neurology
80. Using the CHA2DS2-VASc Score for Refining Stroke Risk Stratification in ‘Low-Risk’ Asian Patients With Atrial Fibrillation
    Tze‐Fan Chao, Chia‐Jen Liu, Kang-Ling Wang, Yenn‐Jiang Lin, Shih‐Lin Chang, Li‐Wei Lo, Yu‐Feng Hu, Ta‐Chuan Tuan, Tzeng‐Ji Chen, Gregory Y.H. Lip et al. · 2014 · Journal of the American College of Cardiology
81. Comparison of the Short-Term Risk of Bleeding and Arterial Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Newly Treated With Dabigatran or Rivaroxaban Versus Vitamin K Antagonists
    Géric Maura, Pierre‐Olivier Blotière, Kim Bouillon, Cécile Billionnet, Philippe Ricordeau, François Alla, Mahmoud Zureik · 2015 · Circulation
82. Revised A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey
    Ron Pisters, Deirdre A. Lane, Robby Nieuwlaat, Hjgm Crijns, Gregory Y.H. Lip · 2012
83. Non-inferiority study design: lessons to be learned from cardiovascular trials
    Stuart J. Head, Sanjay Kaul, Ad J.J.C. Bogers, A. Pieter Kappetein · 2012 · European Heart Journal
84. Effectiveness and Safety of Non–vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses
    Abdulaali R. Almutairi, Lili Zhou, Walid F. Gellad, Jeannie K. Lee, Marion Kimball Slack, Jennifer R Martin, Wei-Hsuan Lo-Ciganic · 2017 · Clinical Therapeutics
85. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI
    Davide Capodanno, Kurt Huber, Roxana Mehran, Gregory Y.H. Lip, David P. Faxon, Christopher Bull Granger, Pascal Vranckx, Renato D. Lópes, Gilles Montalescot, Christopher Paul Cannon et al. · 2019 · Journal of the American College of Cardiology
86. Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation
    Michael D. Ezekowitz, Lars C. Wallentin, Stuart J. Connolly, Amit Parekh, Michael Ross Chernick, Janice M. Pogue, Timothy H. Aikens, Sean Yang, Paul A. Reilly, Gregory Y.H. Lip et al. · 2010 · Circulation
87. Arterial Thromboembolism
    Virginia Luis Fuentes · 2012 · Journal of Feline Medicine and Surgery
88. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis
    Sammy Elmariah, Laura Mauri, Gheorghe D. Doros, Benjamin Zev Galper, Kelly E O'Neill, Philippe Gabríel Steg, Dean J Kereiakes, Robert W. Yeh · 2014 · The Lancet
89. Risks of Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Receiving Warfarin and Treated With Intravenous Tissue Plasminogen Activator
    Ying Xian, Li Liang, Eric Edward Smith, Lee H. Schwamm, Mathew J. Reeves, DaiWai M. Olson, Adrian F. Hernandez, Gregg C. Fonarow, Eric David Peterson · 2012 · JAMA
90. Antithrombotic Therapy in Patients With Chronic Kidney Disease
    Davide Capodanno, Dominick Joseph Angiolillo · 2012 · Circulation
91. Oral bioavailability of dabigatran etexilate ( P radaxa ® ) after co‐medication with verapamil in healthy subjects
    Sebastian Härtter, Regina Sennewald, Gerhard Nehmiz, Paul A. Reilly · 2012 · British Journal of Clinical Pharmacology
92. Use of Dabigatran for Periprocedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial Fibrillation
    Mohamed Bassiouny, Walid I. Saliba, John Rickard, Mingyuan Shao, Albert Sey, Mariam Diab, David O. Martin, Ayman Ali Hussein, Maurice Khoury, Bernard Abi‐Saleh et al. · 2013 · Circulation Arrhythmia and Electrophysiology
93. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring
    Wolfgang Mueck, Stephan Schwers, Jan Julius Stampfuss · 2013 · Thrombosis Journal
94. Social determinants of atrial fibrillation
    Utibe R. Essien, Jelena Kornej, Amber E. Johnson, Lucy Schulson, Emelia J. Benjamin, Jared W. Magnani · 2021 · Nature Reviews Cardiology
95. Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment
    John W. Eikelboom, Martin James O'Donnell, Salim Yusuf, Rafael Díaz, Greg C. Flaker, Robert G. Hart, Stefan Hans Hohnloser, Campbell D. Joyner, Jack Lawrence, Prem Pais et al. · 2010 · American Heart Journal
96. Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: Rationale and design
    S. Claiborne Johnston, J. Donald Easton, Mary Farrant, William G. Barsan, Holly Battenhouse, ROBIN A. CONWIT, Catherine Dillon, Jordan Elm, Anne S. Lindblad, Lewis B. Morgenstern et al. · 2013 · International Journal of Stroke
97. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study
    Di Biase, Luigi, Lakkireddy, Dhanujaya, Trivedi, Chintan, Deneke, Thomas, Martinek, Martin, Mohanty, Sanghamitra, Mohanty, Prasant, Prakash, Sameer, Bai, Rong, Reddy, Madhu et al. · 2015 · Heart Rhythm
98. Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries
    Harriette G.C. Van Spall, Lars C. Wallentin, Salim Yusuf, John W. Eikelboom, Robby Nieuwlaat, Sean Yang, Conrad Kabali, Paul A. Reilly, Michael D. Ezekowitz, Stuart J. Connolly · 2012 · Circulation
99. Effectiveness and Safety of Dabigatran and Warfarin in Real‐World US Patients With Non‐Valvular Atrial Fibrillation: A Retrospective Cohort Study
    Julie C. Lauffenburger, Joel F. Farley, Anil K. Gehi, Denise H. Rhoney, M. Alan Brookhart, Gang Fang · 2015 · Journal of the American Heart Association
100. Implications of the CHA2DS2-VASc and HAS-BLED Scores for Thromboprophylaxis in Atrial Fibrillation
     Gregory Y.H. Lip · 2010 · The American Journal of Medicine